- Previous Close
793.20 - Open
786.50 - Bid 879.40 x --
- Ask 911.00 x --
- Day's Range
793.20 - 793.20 - 52 Week Range
768.80 - 976.80 - Volume
809 - Avg. Volume
203 - Market Cap (intraday)
179.547B - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
35.33 - EPS (TTM)
22.45 - Earnings Date Feb 4, 2025
- Forward Dividend & Yield 34.00 (4.29%)
- Ex-Dividend Date Dec 6, 2024
- 1y Target Est
--
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
www.coloplast.com16,639
Full Time Employees
September 30
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: COLOBC.XC
View MorePerformance Overview: COLOBC.XC
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COLOBC.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COLOBC.XC
View MoreValuation Measures
Market Cap
179.59B
Enterprise Value
201.43B
Trailing P/E
35.32
Forward P/E
29.67
PEG Ratio (5yr expected)
2.93
Price/Sales (ttm)
6.60
Price/Book (mrq)
9.96
Enterprise Value/Revenue
7.45
Enterprise Value/EBITDA
23.75
Financial Highlights
Profitability and Income Statement
Profit Margin
18.69%
Return on Assets (ttm)
9.49%
Return on Equity (ttm)
28.67%
Revenue (ttm)
27.03B
Net Income Avi to Common (ttm)
5.05B
Diluted EPS (ttm)
22.45
Balance Sheet and Cash Flow
Total Cash (mrq)
788M
Total Debt/Equity (mrq)
126.12%
Levered Free Cash Flow (ttm)
-647.75M